The North America Arthritic Therapeutic Market would witness market growth of 4.5% CAGR during the forecast period (2023-2030).
The US market dominated the North America Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $31,321.7 Million by 2030. The Canada market is experiencing a CAGR of 6.8% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.9% during (2023 - 2030).
Adopting arthritic therapeutics hinges on the availability of safe and efficacious treatments that effectively alleviate symptoms, preserve joint function, and enhance overall quality of life. Clinical trials and real-world evidence demonstrating the benefits of various pharmacological and non-pharmacological interventions are crucial in informing treatment decisions and shaping clinical practice guidelines.
The adoption of this is influenced by the availability and accessibility of healthcare infrastructure, like rheumatology clinics, primary care providers, physical therapy facilities, and diagnostic services. Adequate healthcare resources, including trained personnel, medical equipment, and pharmaceutical supplies, are essential for delivering comprehensive arthritis care and implementing evidence-based treatment protocols.
According to the Canadian Institute for Health Information, Canada’s senior population of those 65 and older will expand by 68% over the next 20 years. It has more than tripled in size in the last 40 years. In 2017, it was around 6.2 million. It is anticipated to reach 10.4 million in 2037. This population in Canada is projected to increase by 2.1 times by 2037 from its size in 2017. Arthritis is one of the most common chronic conditions among older adults in Canada. Hence, the factors mentioned above will drive the regional market growth.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $31,321.7 Million by 2030. The Canada market is experiencing a CAGR of 6.8% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.9% during (2023 - 2030).
Adopting arthritic therapeutics hinges on the availability of safe and efficacious treatments that effectively alleviate symptoms, preserve joint function, and enhance overall quality of life. Clinical trials and real-world evidence demonstrating the benefits of various pharmacological and non-pharmacological interventions are crucial in informing treatment decisions and shaping clinical practice guidelines.
The adoption of this is influenced by the availability and accessibility of healthcare infrastructure, like rheumatology clinics, primary care providers, physical therapy facilities, and diagnostic services. Adequate healthcare resources, including trained personnel, medical equipment, and pharmaceutical supplies, are essential for delivering comprehensive arthritis care and implementing evidence-based treatment protocols.
According to the Canadian Institute for Health Information, Canada’s senior population of those 65 and older will expand by 68% over the next 20 years. It has more than tripled in size in the last 40 years. In 2017, it was around 6.2 million. It is anticipated to reach 10.4 million in 2037. This population in Canada is projected to increase by 2.1 times by 2037 from its size in 2017. Arthritis is one of the most common chronic conditions among older adults in Canada. Hence, the factors mentioned above will drive the regional market growth.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Market Report Segmentation
By Application- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Arthritic Therapeutic Market, by Application
Chapter 6. North America Arthritic Therapeutic Market, by Product Type
Chapter 7. North America Arthritic Therapeutic Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Methodology
LOADING...
